Tenofovir: what have over 1 million years of patient experience taught us?

International Journal of Clinical Practice
Anton L Pozniak

Abstract

Several groundbreaking trials and over 1 million years of patient experience have established tenofovir as an important component of HIV treatment. Tenofovir has demonstrated potent antiviral efficacy, with a low risk of developing resistance when used as part of an effective combination regimen. It is generally well tolerated, with a low risk of lipoatrophy and a favourable effect on lipid profile compared with older nucleoside analogue agents such as stavudine or zidovudine. Clinical data suggest that switching from thymidine analogues to a tenofovir-containing regimen can benefit patients with lipid abnormalities or lipoatrophy. This article reviews the development of tenofovir, including pivotal studies that have influenced HIV clinical practice.

References

Sep 8, 2001·AIDS·A L MooreM A Johnson
Dec 3, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·David VerhelstJerome Rossert
Dec 24, 2002·The American Journal of the Medical Sciences·Steven Coca, Mark A Perazella
Feb 4, 2003·The Journal of Antimicrobial Chemotherapy·Damian J McColl, Michael D Miller
Mar 28, 2003·AIDS·Caroline CréputDominique Nochy
Apr 10, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alexandre KarrasJean-Michel Molina
Sep 11, 2003·Annals of Internal Medicine·Kathleen SquiresUNKNOWN Study 907 Team
Oct 4, 2003·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Raymond F Schinazi
Nov 26, 2003·The Journal of Infectious Diseases·Franck S RousseauUNKNOWN FTC-102 Clinical Trial Group
Mar 26, 2004·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·C AmielM C De Vernejoul
Jul 14, 2004·JAMA : the Journal of the American Medical Association·Joel E GallantUNKNOWN 903 Study Group
Aug 21, 2004·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Peter J Piliero
Oct 30, 2004·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·S LandonioG M Vigevani
Mar 26, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Joel E GallantRichard D Moore
May 13, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Samir K GuptaLynda A Szczech
Nov 15, 2005·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Simon P JonesGraeme J Moyle
Jan 20, 2006·The New England Journal of Medicine·Joel E GallantUNKNOWN Study 934 Group
Mar 25, 2006·The Journal of Antimicrobial Chemotherapy·Vincent SorianoMarina Nuñez
Oct 21, 2006·AIDS·Graeme J MoyleUNKNOWN RAVE (Randomized Abacavir versus Viread Evaluation) Group UK
Nov 16, 2006·HIV Medicine·B GazzardUNKNOWN Writing Committee, British HIV Association
May 17, 2007·International Journal of Clinical Practice·R JonesJ Levy
Feb 5, 2010·Best Practice & Research. Clinical Rheumatology·Francis Berenbaum

❮ Previous
Next ❯

Citations

Nov 16, 2011·Antimicrobial Agents and Chemotherapy·Karyn McFaddenIrwin Chaiken
Mar 3, 2010·The AAPS Journal·Ahmed S ZidanMansoor A Khan
Feb 20, 2010·Therapeutics and Clinical Risk Management·Iwen F GrigsbyKim C Mansky
Dec 15, 2010·Expert Opinion on Drug Delivery·Najeh Maissar KhalilRubiana Mara Mainardes
Dec 23, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Rose I OkonkwoEmmanuel E Effa
May 19, 2009·Journal of Controlled Release : Official Journal of the Controlled Release Society·Alejandro SosnikAngel M Carcaboso
Jun 3, 2015·Infectious Diseases and Therapy·Andrew Ustianowski, Joop E Arends
Dec 22, 2017·Journal of Translational Medicine·A Gonzalez-SernaE Ruiz-Mateos
Jan 5, 2010·Current Opinion in HIV and AIDS·Nathan Ford, Alexandra Calmy
Dec 18, 2010·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Helen BygraveKatharina Kranzer
Feb 28, 2018·The Journal of Organic Chemistry·Zhoulong FanAo Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Related Papers

The Annals of Pharmacotherapy
Shellee A Grim, Frank Romanelli
Journal of Clinical Pharmacology
David WarnkeZelalem Temesgen
Annual Review of Pharmacology and Toxicology
Craig W HendrixEdward J Fuchs
© 2022 Meta ULC. All rights reserved